USE OF THE COMBINATION OF AZD1222 AND RAD26-S FOR THE PREVENTION OF COVID-19

Abstract

The study, which aimed to study the body's immune response and evaluate the safety of the vaccine combination, included 100 subjects over 18 years of age who received AZD1222 (based on the nonreplicating vector ChAdOx1) and rAd26-S (a component of the recombinant adenovirus type 26 Gam-COVID vaccine) - Vac, Sputnik V: Manufacturing - AstraZeneca is a British-Swedish pharmaceutical company registered in the UK, National Research Center for Epidemiology and Microbiology named after N.F.Gamaleya of the Russian Ministry of Health) in accordance with the approved research protocol. The immune response was assessed by the level of antibodies in blood samples before vaccination and 15, 29, 57 and 180 days after vaccination, by the level of antibodies to the S-protein and RBD (receptor binding domain), as well as neutralizing antibodies to the SARS-CoV-2 virus. The results of the study showed that the use of a combination of vaccine components AZD1222 and rAd26-S as a heterologous prime-booster immunization induced a strong immune response against SARS-CoV-2 protein antigens and was characterized by a favorable and manageable safety profile.